By Indication

Ventilator-Associated Pneumonia (VAP) Market Analysis

Cross-industry research covering Ventilator-Associated Pneumonia (VAP) across 1 market reportspanning Pharmaceuticals.

1 Reports
1 Industries

Reports Covering Ventilator-Associated Pneumonia (VAP)

Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR

Pharmaceuticals·Market: USD 25.3 Billion (2025)·CAGR: 6.4%

VAP remains the highest-mortality HAI in ICU settings, with antipseudomonal beta-lactams and inhaled tobramycin as the primary pharmacotherapy backbone. Prone positioning trials in pneumonia patients (nct:NCT06966310) are generating RWE on non-pharmacological adjuncts that may reduce antibiotic course duration and per-episode drug cost.

17%

Market Share

6.0%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments